—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Genmab AS (GMAB) — Technical state

As of 2026-11-10 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 50 out of 100 (momentum 93 · quality 73 · valuation 19), as of 2026-11-11.
  • Signal: Uptrend stack intact — Trades +35% vs the 50-day and +73% vs the 200-day average, 9.8% below the 52-week high and +128.9% off the 52-week low; a golden cross printed 54 sessions ago. Computed from daily closes. (as of 2026-11-10)
  • Trend: Genmab AS trades 35.0% above its 50-day and 73.0% above its 200-day moving average. (as of 2026-11-10)

Genmab develops antibody-based medicines for cancer and other diseases, working from Copenhagen with additional roots in Denmark's biotech sector. It markets treatments such as Tivdak and Epkinly for blood and cervical cancers, and shares several approved drugs, including Darzalex and Tecvayli, through partnerships with larger pharmaceutical firms.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the GMAB overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Uptrend stack intact

Trades +35% vs the 50-day and +73% vs the 200-day average, 9.8% below the 52-week high and +128.9% off the 52-week low; a golden cross printed 54 sessions ago. Computed from daily closes.

Ranked #44 on today’s Directional Flow — Getting stronger list (scan of 2026-11-10).

The moving-average stack

Continue: the GMAB chart & overview · quality & forensics · the earnings record · the signal board

FAQ · from the current data · as of 2026-11-10

Quick answers

What is the current Closelooknet signal on GMAB?

Uptrend stack intact — Trades +35% vs the 50-day and +73% vs the 200-day average, 9.8% below the 52-week high and +128.9% off the 52-week low; a golden cross printed 54 sessions ago. Computed from daily closes. As of 2026-11-10; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is GMAB above its 50-day and 200-day moving averages?

As of 2026-11-10, Genmab AS trades +35% above its 50-day and +73% above its 200-day average, with the 20-day +13.3% away.

How far is GMAB from its 52-week high?

9.8% below the 52-week high and 128.9% above the 52-week low, as of 2026-11-10.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.